CRISPR Therapeutics Reports Fourth Quarter and Full Year 2016 …Yahoo FinanceBASEL, Switzerland and CAMBRIDGE, Mass., March 10, 2017– CRISPR Therapeutics,, a biopharmaceutical company focused on creating transformative …and more »… Continue reading
|
Stem Cell Treatment May Restore Vision to Patients with Damaged Corneas
Georgia Tech News Center Researchers working as part of the University of Georgia’s Regenerative Bioscience Center have developed a new way to identify and sort stem cells that may one day allow clinicians to restore vision to people with damaged corneas using the patient’s … |
Research Horizons |
Stem Cell Treatment May Restore Vision to Patients with Damaged Corneas
Research Horizons Researchers working as part of the University of Georgia’s Regenerative Bioscience Center have developed a new way to identify and sort stem cells that may one day allow clinicians to restore vision to people with damaged corneas using the patient’s … |
IEEE Spectrum |
With Synthetic Biology Software, Geneticists Design Living Organisms From Scratch
IEEE Spectrum Nothing like BioStudio existed when Boeke asked Sarah Richardson to help him out. Then a PhD candidate at Johns Hopkins University (and now chief scientific officer at the synthetic biology startup Ignition Genomics), Richardson says existing software … Scientists create ‘designer yeast’ in major step toward synthetic lifeWashington Post A big step towards an artificial yeast genomeThe Economist Biology team makes breakthrough in synthetic yeast projectPhys.Org Reuters –The Scientist –Gizmodo all 46 news articles » |
Pharmaceutical Processing |
Clinical Trials Start for Stem Cell Alzheimer’s Drug in US
Pharmaceutical Processing Biostar Stem Cell Research Institute, which is co-operated by Nature Cell and R Bio, has developed a technology for culturing autologous fat stem cells. The institute has invested more than KRW 300 billion ($261 million) in its research and development … |
Xconomy |
Tocagen Plans IPO to Finance Trials of Gene Therapy in Brain …
Xconomy Gene therapy developer Tocagen is preparing an initial public stock offering to finance clinical trials of its experimental treatment for a form of brain c. Tocagen seeks $86M IPO to fund cancer gene therapy trial …FierceBiotech Gene Therapy Developer Tocagen Files for $86M IPO | GENGenetic Engineering & Biotechnology News (press release) Tocagen readies IPO | Seeking AlphaSeeking Alpha |